Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2018-01-23 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于控股股东股权解除质押及质押的公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the release and new pledging of shares by its controlling shareholder. It details the number of shares released from pledge, newly pledged shares, pledge dates, pledgees, and the proportion of shares involved. The document includes tables with shareholding and pledge details and mentions the completion of pledge registration procedures. There is no financial statement, earnings data, or management discussion. The content is focused on share pledge status updates by a major shareholder, which fits the category of a Major Shareholding Notification rather than a full financial report or other categories. The document length is short (1845 characters), and it is a direct announcement, not a report publication or certification. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2018-01-23 Chinese
关于增资入股金仕生物科技（常熟）有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement about Shenzhen Xinlitai Pharmaceutical Co., Ltd. investing RMB 100 million to increase capital and acquire a 10.81% equity stake in Jinshi Biotechnology (Changshu) Co., Ltd. It includes transaction overview, parties involved, financial data of the target company, terms of the investment, strategic rationale, and risk disclosures. The document is a formal announcement of a capital investment transaction, describing the financing activity and equity acquisition. It does not contain financial statements or quarterly/yearly financial results, nor is it a report or presentation. It is not a regulatory filing or certification letter. The content fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through equity investment.
2018-01-19 Chinese
关于参股四川锦江电子科技有限公司暨增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's acquisition of a 12% equity stake and capital increase in another company, Sichuan Jinjiang Electronics Technology Co., Ltd. It details the transaction overview, parties involved, financial data of the target company, transaction terms, and the strategic rationale behind the investment. There is no indication that this is a full financial report, earnings release, or regulatory filing. The content focuses on a capital investment transaction and financing activity by the company. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2018-01-16 Chinese
关于硫酸氢氯吡格雷片（75mg）第一批通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (718 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the inclusion of their drug (Clopidogrel Hydrogen Sulfate Tablets 75mg) in a government-approved list for quality and efficacy consistency evaluation. It contains no financial data, no detailed financial statements, no management discussion, or regulatory certifications. It is an official company announcement about a product approval and related market outlook, not a financial report or detailed filing. The document is not a report itself but an announcement of a regulatory or product status update. Given the content and length, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-12-29 Chinese
关于增资苏州金盟生物技术有限公司的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the progress of capital increase in its subsidiary Suzhou Jinmeng Biotechnology Co., Ltd. It details the board resolution approving the use of company funds to increase capital, changes in registered capital, shareholding percentages, and completion of business registration changes. The document is short (981 characters) and focuses on a corporate financing event related to capital injection and shareholding changes. It is not a full financial report, audit, or earnings release. It is not a report publication announcement or certification. The content fits best under Capital/Financing Update (CAP) as it provides an update on the company's financing activity and capital structure changes.
2017-12-22 Chinese
关于使用自有资金增资苏州金盟生物技术有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the use of its own funds to increase capital in its controlled subsidiary, Suzhou Jinmeng Biotechnology Co., Ltd. It details the investment amount, shareholding changes, board approval, and the purpose and impact of the capital increase. The document is a formal disclosure of a financing activity related to capital structure changes, specifically an equity injection into a subsidiary. It does not contain financial statements or comprehensive financial analysis, nor is it a report or transcript. The content fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes. The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is the actual announcement of a capital increase transaction. Therefore, the correct classification is CAP with high confidence.
2017-12-04 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.